EMAIL THIS PAGE TO A FRIEND

Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine

[Radiation lesion formation and character of repair processes in the hematopoietic system of primates exposed to continuous and fractionated gamma-irradiation by equally effective doses].


PMID 23402142

Abstract

The article is dedicated to comparison of the biological effectiveness of continuous and fractionated gamma-irradiation of rhesus macaques by equally effective doses. These radiation conditions are broadly used in radiobiological experiments. Specifically, they are applied in modeling radiation effects on cosmonauts during extended exploration mission. A model of radiation damage and repair on the cell, tissue and organism levels, i.e., a model of effective residual dose responsible for change in mammals' resistance to irradiation of varying duration was used to calculate equally effective doses in the experiment with primates subject to continuous and fractionated exposure. The authors publish data related to formation of radiation lesion and rate of ensuing hemopoiesis reparation. Two groups of animals were compared in resistance modification followed after testing by acute irradiation. The test was to reproduce a radiation situation for cosmonauts in the event of a cannonade of powerful solar proton events resulting in an effective residual dose of 1 Sv total The experiment evidenced close resemblance of the hemopoietic effects in primates exposed to the compared radiation conditions.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

G6378
Glucose-6-phosphate Dehydrogenase from baker's yeast (S. cerevisiae), Type XV, lyophilized powder, 200-400 units/mg protein (modified Warburg-Christian)
G7877 Glucose-6-phosphate Dehydrogenase from baker's yeast (S. cerevisiae), Type VII, ammonium sulfate suspension, ≥200 units/mg protein
G4134 Glucose-6-phosphate Dehydrogenase from baker's yeast (S. cerevisiae), Type IX, lyophilized powder, 200-400 units/mg protein (modified Warburg-Christian)
G5885 Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, lyophilized powder, 550-1,100 units/mg protein (biuret)
G8404 Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, recombinant, expressed in E. coli, ammonium sulfate suspension, 550-1,100 units/mg protein (biuret)
G5760 Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, Type XXIII, ammonium sulfate suspension, 550-1,100 units/mg protein (biuret), ≥2.0 mg/mL Biuret
G8529 Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, recombinant, expressed in E. coli, lyophilized powder, 550-1,100 units/mg protein (biuret)
G2921
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, BioUltra, recombinant, expressed in E. coli, ammonium sulfate suspension, ≥95% (SDS-PAGE), ≥550 units/mg protein (biuret)
G8289 Glucose-6-phosphate dehydrogenase from torula yeast, ammonium sulfate suspension, 300-600 units/mg protein (biuret)